THALES
10.4.2024 11:40:33 CEST | Business Wire | Press release
Thales, the leading global technology and security provider, today announced a collaboration leveraging its CipherTrust Data Security Platform (CDSP) to support End-To-End Data Protection (E2EDP) on Google Cloud, using Confidential Computing (CC) from Google Cloud and trusted cloud independent attestation provided by Intel Trust Authority (ITA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410848317/en/
©Thales
The effort is a step forward in data security, giving enterprises additional controls to protect their data at rest, in transit, and in use.
“As more enterprises migrate their data and workloads to the cloud, there is an increasing demand to safeguard the privacy and integrity of the data, especially those sensitive workloads that include intellectual property, AI models and valuable personal information. This collaboration enables enterprises to protect and control their data at rest, in transit and in use with fully verifiable attestation. Our close collaboration with Google Cloud and Intel increases our customers' trust in their cloud migration,” said Todd Moore, Vice President of Data Security Products at Thales.
A majority of the 2023 Thales Cloud Security Study respondents reported having a significant amount of sensitive data stored and in use in the cloud. Consequently, safeguarding sensitive data and associated workloads when stored or in use, is an increasing priority, especially for highly regulated industries such as financial services and healthcare. Thales's collaboration with Intel and Google Cloud provides certifiable controls for enterprises to fully protect their data end-to-end.
Purnam Sheth, Vice President and General Manager: Trust and Security Products, SATG at Intel: “Creating this groundbreaking, seamless data security platform in Google Cloud meets customers’ complex requirements for data protection, controlled access and security, and adherence to compliance for data at rest, in transit and in use. Foundational Intel® Trust Domain Extensions Confidential Compute and Intel® Trust Authority gives enterprises assurance of the integrity of their workloads and guards at all stages of data management. This valuable collaboration between Thales, Google Cloud and Intel makes this possible.”
This security platform is based on the principle of separation of duties, where the customer remains in control of the encryption keys and their location. This approach enhances trust by holding each stakeholder responsible for their respective roles and reduces the ability for a malicious actor to access code and data at rest, in transit and while being executed.
Customers can migrate existing workloads with sensitive data or create new workloads needing zero trust, confidential computing and Confidential AI to this security platform in Google Cloud to broaden data security, attestation and set the right authorizations. With end-to-end data protection, multiple parties can securely collaborate on various use cases, such as Confidential AI datasets and models as needed while preserving privacy, confidentiality, and compliance with privacy regulations.
The Thales CipherTrust Data Security Platform uses Intel Trust Authority as a zero-trust, independent attestation service for advanced security and scalable confidential computing. Consistent attestation to Trusted Execution Environments (TEE) that are based on Intel Trust Domain Extensions. This single, consistent attestation process provides assurance to any relying party that the TEE and any data and workloads running within it have not been compromised.
Brian Roddy, VP, Product Management, Google Cloud: “Google Cloud is committed to providing our customers secure, private and reliable environments for their workloads, and our Confidential Computing portfolio plays a critical role in this effort. Offering our customers solutions like Thales’ encryption key management expertise, combined with Intel’s Trust Authority attestation, enables the choice of even stronger privacy controls.”
The collaboration comes as Thales is recognized for its achievements in the Google Cloud ecosystem. For the second year in a row, Thales has received the 2024 Google Cloud Technology Partner of the Year Award for Security - Data Protection.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Cybersecurity and Digital Identity. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Artificial Intelligence, Edge computing, 6G and cybersecurity.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410848317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
